Research can have a profound impact on providing better health for Saskatchewan people. Research has helped develop better drug regimens and can also help identify specific screening or early detection programs that can reduce the prevalence of cancer.
Cancer Agency researchers, scientists and clinicians work hard each year securing grants from institutions and organizations to ensure this important work continues.
2018-19 Funded Research Grants
| Saskatchewan Cancer Agency Funded Research Grants | Researcher | Award Period | Total Amount Awarded | 2018-19 Amount Awarded |
| Identifying targets for combination therapy with Entinostat in triple negative breast cancer | Dr. Keith Bonham | 2017-19 | $200,000 | $100,000 |
| Adherence to oral chemotherapies among pediatric oncology patients using medication event monitoring systems (MEMS) | Dr. Amy Morris | 2017-19 | $38,282 | $13,660 |
| Role of the bone marrow microenvironment in multiple myeloma development and progression | Dr. Julie Stakiw | 2017-19 | $199,200 | $99,600 |
| Identifying EphB6-deficient breast cancer tumours for clinical trials | Dr. Sunil Yadav | 2017-19 | $163,350 | $81,675 |
| Identifying biomarkers and developing molecular probes for radioimmunotherapy of breast cancer | Dr. Arun Sudarsan | 2017-19 | $83,000 | $42,000 |
| Targeting cancer progression genes upregulated in CREB3L1-deficient breast cancer cells | Dr. Shari Smith | 2017-19 | $60,000 | $15,000 |
| Exploiting the synthetic dosage lethal interactions of Polo-like Kinase 1 for cancer therapeutics | Chelsea Cunningham | 2017-19 | $47,000 | $24,000 |
| FOLFIRI alternate with FOLFOX in untreated metastatic gastric and esophageal adenocarcinoma | Dr. Shahid Ahmed | 2018-20 | $100,138 | $55,069 |
| New targets for metastatic breast cancer | Dr. Deborah Anderson | 2018-20 | $200,000 | $100,000 |
| Characterization of the cell surface protein GPR112 as a potential cancer drug target | Dr. Franco Vizeacoumar |
2018-20 | $200,000 | $100,000 |
| Therapeutic immunity of heterlogous HER2-specific HuRt-Texo vaccination against transtuzumab-resistant breast cancer in BLT/NSG mice | Dr. Jim Xiang | 2018-20 | $200,000 | $100,000 |
| Does second line therapy improve survival of individuals with biliary tract and gallbladder cancers | Dr. Zaidi Adnan | 2018-19 | $40,934 | $40,934 |
| Beneficial cytotoxic T lymphocytes derived from irreversible electroporation ablation of breast cancer | Dr. Aizhang Xu | 2018-20 | $83,000 | $41,000 |
| Exploring the landscape of circular RNA expression in breast cancer | Dr. Archana Kumari | 2018-20 | $83,000 | $41,000 |
|
Funded Research Grants |
Organization Funding Received From | Researcher | Award Period | Total Amount Awarded | 2018-19 Amount Awarded |
| Polokinase and drug resistance in pancreatic cancer | Cancer Research Society | Dr. Franco Vizeacoumar | 2017-19 | $120,000 | $60,000 |
| Critical role of FAK/RhoA in regulation of mTORC1/PKM2 pathway controlling epithelial-mesenchymal transition of triple-negative breast cancer | College of Medicine, University of Saskatchewan | Dr. Jim Xiang | 2018 | $30,000 | $30,000 |
| Identification of new drugs to treat triple negative breast cancer | College of Medicine, University of Saskatchewan | Dr. Deborah Anderson | 2018 | $30,000 | $30,000 |
| High throughput molecular imaging platform | Canadian Foundation for Innovation | Dr. Franco Vizeacoumar | 2015-20 | $1,259,322 | $22,668 |
| Role of Individualized Intervention(s) on Quality of Life and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer: MyChoice Study | College of Medicine, University of Saskatchewan | Dr. Shahid Ahmed | 2018 | $24,028 | $24,028 |
| Functional dissection of epigenetic silencing machinery | Natural Sciences and Engineering Research Council | Dr. Franco Vizeacoumar | 2014-20 | $200,000 | $40,000 |
| Distinct regulation of T cell fate and memory via differentially IL-2- and IL-7-activated mTORC1-KIF13A-M6PR axis and AMPK-FOXO-Eomes pathway | Canadian Institutes of Health Research | Dr. Jim Xiang | 2017-21 | $480,000 | $120,000 |
| A systematic genome-wide effort to identify and validate targetable synthetic dosage lethal inter-actions of mitotic kinases in cancer cells | Canadian Institutes of Health Research | Dr. Franco Vizeacoumar | 2018-23 | $592,875 | $118,575 |
| Systematic profiling of circular RNAs essential for the survival of cancer cells | Canadian Institutes of Health Research | Dr. Franco Vizeacoumar | 2018-23 | $573,750 | $114,750 |
| SOTAR leading to an epidemiological study of all causes of death and longevity in Canadians occupationally exposed to ionizing radiation | Candu Owners Group | Dr. Gavin Cranmer-Sargison | 2018 | $60,500 | $60,500 |
200-4545 Parliament Ave
639-625-2010